Insights about U.S. Stocks that landed in the Red-Zone during Wednesday’s trade, are depicted underneath:

Middleby Corp (NASDAQ:MIDD)’s shares dwindled -5.22%, and closed at $101.31.

Middleby Corp. (MIDD), a leading worldwide manufacturer of equipment for the commercial foodservice, food processing, and residential kitchen industries, stated net sales and earnings for the fourth quarter and full fiscal year ended January 3, 2015. Net earnings for the fourth quarter were $51,749,000 or $0.91 diluted earnings per share on net sales of $434,995,000 as contrast to the preceding year fourth quarter net earnings of $49,921,000 or $0.87 diluted earnings per share on net sales of $377,420,000. Net earnings for the fiscal year ended January 3, 2015 were $193,312,000 or $3.40 diluted earnings per share on net sales of $1,636,538,000 as contrast to net earnings of $153,928,000 or $2.74 diluted earnings per share on net sales of $1,428,685,000 in the preceding year.

2014 Fourth Quarter and Full Year Financial Highlights:

• Net sales raised 15.3% in the fourth quarter and 14.5% for the full fiscal year of 2014 over the comparative preceding year periods. Not including the influence of attainments, sales raised 7.4% during the fourth quarter and 8.4% for the full year.
• Net sales at the corporation’s Commercial Foodservice Equipment Group raised 14.8% in the fourth quarter and 16.3% for the full fiscal year of 2014 over the comparative 2013 periods. During fiscal 2013, the corporation accomplished the attainments of Celfrost and Wunder-Bar. During fiscal 2014, the corporation accomplished the attainments of Market Forge and Concordia. Not including the influence of these attainments, sales raised 9.0% in the fourth quarter and 8.9% for the full year.
• Net sales at the corporation’s Food Processing Equipment Group raised 6.6% in the fourth quarter and 7.1% for the full fiscal year of 2014 as contrast to 2013. During fiscal 2014, the corporation accomplished the attainment of Processing Equipment Solutions. Not including the influence of this attainment, sales raised by 1.1% in the fourth quarter and 3.7% for the full year.

The Middleby Corporation designs, manufactures, markets, distributes, and services commercial foodservice and food processing, and residential kitchen equipment in the United States, Canada, Asia, Europe, the Middle East, and Latin America.

Geron Corporation (NASDAQ:GERN), declined - 5.07%, and closed at $2.81.

Geron Corporation (GERN), stated financial results for the fourth quarter and year ended December 31, 2014 and recent events.

Fourth Quarter 2014 Results:

Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, contrast to $9.3 million, or $0.07 per share, for the comparable 2013 period. Proceeds for the fourth quarter of 2014 were $178,000 contrast to $225,000 for the comparable 2013 period. The corporation ended 2014 with $170.6 million in cash and investments, which comprised of receipt of an upfront payment of $35.0 million for the license rights granted by the corporation to Janssen Biotech, Inc. (“Janssen”) under the exclusive partnership and license contract (the “Partnership Contract”) reached between the parties in November 2014, which has been recorded as deferred proceed as of December 31, 2014.

Total operating expenses for the fourth quarter of 2014 were $9.2 million contrast to $9.5 million for the comparable 2013 period. Research and development expenses for the fourth quarter of 2014 were $4.4 million contrast to $5.1 million for the comparable 2013 period. General and administrative expenses for the fourth quarter of 2014 were $4.8 million contrast to $4.0 million for the comparable 2013 period. Operating expenses for the 2013 fourth quarter also comprised of restructuring charges of $430,000 in connection with the corporation`s decisions to discontinue its discovery research programs and close its research laboratory facility in 2013.

Geron is a clinical stage biopharmaceutical corporation focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Cytori Therapeutics Inc (NASDAQ:CYTX), dipped -5.00%, and closed at $1.14.

Cytori Therapeutics, Inc. (CYTX), offered a business and financial performance update in its presentation at the Cowen and Corporation 35th Annual Health Care Conference in Boston recently. The corporate presentation comprises certain top-line preliminary unaudited financial results for the quarter and full year ended December 31, 2014 and select performance guidance for the full-year 2015.

• Preliminary cash and debt balances at December 31, 2014 of about $14.6 million and $25 million, respectively.
• Preliminary Q4 and full-year 2014 operating cash burn of about $4.9 million and $30.3 million; respectively.
• Preliminary Q4 and full-year 2014 product proceed of about $2.5 million and $5.0 million, respectively.
• Preliminary Q4 and full-year 2014 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, of a profit of about $44 thousand and a loss of about $3.9 million, respectively.
• Preliminary Q4 and full-year 2014 contract proceed of about $1.3 million and $2.6 million, respectively.
• Estimation of 2015 operating cash burn of about $25 million.
• Full-year 2015 product proceed predictable to be within a range from $5 million and $8 million.
• Full-year 2015 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, predictable to be a profit ranging from $100 thousand and $300 thousand.
• Full-year 2015 contract proceed predictable to be within a range from $6 million and $8 million.

“During 2014, we were able to combine expense reductions with continued achievement of our business objectives. For example, we reduced our quarterly operating cash burn from a high of $9.2 million in Q2 2014 to $4.9 million in Q4 2014 and restructured our sales and marketing organization to essentially breakeven by Q4 2015,” said Dr. Marc H. Hedrick, President and Chief Executive Officer.

Cytori Therapeutics is a late stage cell therapy corporation developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.

Coeur Mining Inc (NYSE:CDE), dropped -4.99%, and closed at $5.71.

Formerly on February 20, Coeur Mining, Inc. (CDE), declared the completion of its attainment of the Wharf gold mine from Goldcorp, Inc. following the formerly declared contract.

Under the terms of the contract, Coeur purchased all of the issued and outstanding shares of the ordinary stock of Wharf from a partner of Goldcorp in exchange for $105 million in cash, subject to customary post-closing working capital adjustments.

Wharf is predictable to produce 74,000 — 78,000, gold ounces for the remainder of 2015 at a cost applicable to sales per gold equivalent ounce of $750 - $825.

Coeur Mining, Inc., through its auxiliaries, is engaged in the ownership, operation, exploration, and development of silver and gold mining properties primarily in the United States, Mexico, Bolivia, Argentina, Australia, Ecuador, and Chile.